147663-01-2

Basic information

• Product Name: (S)-9-Hydroxy Risperidone
• Synonyms: (S)-9-Hydroxy Risperidone;(9S)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro -9-hydroxy-2-Methyl-4H-pyrido[1,2-a]pyriMidin-4-one;(S)-9-Hydroxy Risperidone ((S)-Paliperidone);Paliperidone S-Isomer;(S)-Paliperidone;Pure Paliperidone (-);9-(S)-Paliperidone;3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9(S)-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
• CAS NO: 147663-01-2
• Molecular Formula: C23H27FN4O3
• Molecular Weight: 426.4838832
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Heterocycles, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 147663-01-2.mol
• Article Data: 61

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-9-Hydroxy Risperidone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-9-Hydroxy Risperidone(147663-01-2)
• EPA Substance Registry System: (S)-9-Hydroxy Risperidone(147663-01-2)

Safety Data

• Hazardous Substances Data: 147663-01-2(Hazardous Substances Data)

Usage

Uses

The S-enantiomer metabolite of Risperidone, a combined serotonin (5-HT2) and dopamine (D2) receptor antagonist.

Upstream product

• 108-20-3 di-isopropyl ether 
• 84163-13-3 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole hydrochloride 
• 108-18-9 diisopropylamine 
• 67-63-0 isopropyl alcohol 
• 199739-10-1 paliperidone palmitate 
• 130049-82-0 3-(2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
• 1117803-76-5 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-acetyloxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 
• 1109182-35-5 C₂₈H₃₅FN₄O₄ 
• 1104389-11-8 paliperidone hydrochloride 
• 84163-77-9 6-fluoro-3-(4-piperidinyl)benzo[d]isoxazole 
• 1204248-69-0 C₂₃H₂₆FN₅O₃ 
• 1189516-65-1 R₁₂₅₂₃₉ 
• 766485-15-8 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-4H-pyrido-[1,2-a]pyrimidin-4-one 
• 849727-63-5 (±)-3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride 

Downstream Products

• 1172995-11-7 paliperidone myristate 
• 1172995-13-9 paliperidone stearate 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER

In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Paliperidone intermediate and method for producing paliperidone using the same

Disclosed are novel intermediates of paliperidone which are used as a therapeutic agent for schizophrenia, and to a method for producing paliperidone using the same. The intermediates are a compound represented by chemical formula 3 and a compound represented by chemical formula 5. The method for producing paliperidone comprises a step of conducting a reaction of a compound represented by chemical formula 5 and an acid compound. In the chemical formulas 3 and 5, R is a silyl group, a hydrocarbon group having 1-20 carbon atoms, a protecting group represented by -R_1OR_2 or -R_1SR_2, or a protecting group represented by -C(=O)R_2. In particular, R_1 is a methylene group or a carbonyl group, and R_2 is a substituted or unsubstituted alkyl group, an aryl group, or an alkylaryl group, wherein R_1 and R_2 can bond to each other to form a ring.COPYRIGHT KIPO 2018

Preparation method for paliperidone palmitate

The invention discloses a preparation method for paliperidone palmitate. The preparation method comprises the following steps: step 1, synthesis of 3-(2-hydroxyethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyltetrahydro-pyridino[1,2-alpha]pyrimidin-4-one; step 2, synthesis of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyltetrahydro-pyridino[1,2-alpha]pyrimidin-4-one; step 3, synthesis of paliperidone; and step 4, synthesis of paliperidone palmitate. Compared with the prior art, the preparation method provided by the invention has the advantages of short reaction time, low cost, controllability of impurities, easiness in purification, high product purity and high yield.